For instance, in the KEYNOTE-355 trial, the treatment of TNBC with the combined administration of pembrolizumab programmed cell death protein (PD)-1 inhibitor and chemotherapy drugs (paclitaxel, nab-paclitaxel, or carboplatin/gemcitabine) was investigated to identify improved progression-free survival in patients with locally recurrent inoperable or metastatic TNBC that show tumor expression of PD-L1 [65]. The gene discussed is CD274; the disease is neoplasm.